CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Polyethylene Glycol (PEG 3350) +2 moredrug
Likely dose
Polyethylene Glycol (PEG 3350) 17 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01885104
NCT01885104Phase 2Completed
CompareCT.gov

Evaluation of Oral Tolerance MiraLAX Solution Concentrate in Subjects With Chronic Constipation

Bayer·interventional·Posted Jun 24, 2013·Updated Mar 11, 2015

In Brief

A Phase 2 clinical trial evaluating Polyethylene Glycol (PEG 3350), Placebo, and 1 other intervention for Constipation. Completed, enrolled 65 participants.

Detailed Summary

The purpose of this study is to compare the safety and tolerability of oral ingestion of PEG 3350 solution concentrate to oral ingestion of a placebo solution concentrate, in participants with constipation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 24, 2013
Enrollment StartApr 1, 2013
Primary CompletionSep 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.0 years ago

Interventions

Polyethylene Glycol (PEG 3350)drug

Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.

Placebodrug

Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.

Bisacodyl laxative tablets (rescue medication)drug

5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.